MedTech Terms
    The authoritative reference
    All terms

    Premarket Cybersecurity Submission

    The bundle of cybersecurity artifacts a sponsor includes in a 510(k), De Novo, PMA, or HDE submission for a cyber device.

    Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed May 5, 2026

    Definition

    A premarket cybersecurity submission is the formal collection of cybersecurity documentation - threat model, risk assessment, security architecture views, SBOM, vulnerability management plan, security testing results, and end-user labeling - that FDA requires under section 524B for any cyber device. The September 2023 FDA guidance "Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions" describes the expected content in detail, replacing the 2014 and 2018 draft guidances.
    What the regulation says
    FDA expects the submission to demonstrate a Secure Product Development Framework (SPDF) - meaning cybersecurity is engineered in, not bolted on. Reviewers look for: a comprehensive STRIDE or similar threat model traceable to the device's intended use; a cybersecurity risk assessment integrated with ISO 14971 safety risk; security architecture views (global system, multi-patient harm, updateability/patchability, security use case); a CycloneDX or SPDX SBOM with vulnerability and end-of-support information; testing evidence (vulnerability scanning, penetration testing, fuzz testing, SAST/DAST); a coordinated vulnerability disclosure process; and labeling that informs operators about the device's security posture.

    What this means in practice

    The premarket package is the single largest cybersecurity deliverable a MedTech team produces. Most successful teams build it incrementally throughout development rather than at the end - threat model in design phase, SBOM from CI/CD, pen test before V&V freeze, labeling alongside the IFU. Late-stage scrambling to assemble the package is the leading cause of Refuse-to-Accept findings and Major Deficiency letters.
    Common pitfalls
    • •Building the cybersecurity package after V&V is frozen - gaps surface that require design changes.
    • •Submitting a threat model that lists only generic threats (e.g., 'malware') without device-specific attack paths.
    • •Treating penetration testing as a one-shot at submission instead of a recurring activity tied to design changes.
    • •Failing to integrate cybersecurity risk into the ISO 14971 risk management file - FDA expects one unified risk picture.

    Frequently asked questions

    The 2014 guidance (premarket) and 2016 guidance (postmarket) were short and high-level. The 2018 draft introduced Tier 1/Tier 2 device tiers. The September 2023 final guidance is the current authority - it consolidates premarket expectations and operationalizes the section 524B statutory requirements.

    Cross-references

    Uses

    Concepts or artefacts this term builds on.

    Used by

    Things that build on this term.

    See also

    Closely related context worth reading.

    Primary references

    3 sources
    Link health: 1 verified 2 bot-blocked· last checked 2026-05-09
    FDA·2ISO/IEC·1
    1. 1
      Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions (Sept 2023)
      Bot-blocked
      FDAfda.gov
    2. 2
      FDA Digital Health Center of Excellence - Cybersecurity
      Bot-blocked
      FDAfda.gov
    3. 3
      IEC 81001-5-1: Health software - Security activities in the product life cycle
      Verified
      ISO/IECiso.org

    Inline markers like [1] jump to the matching reference above.